Antineoplastic Medicines Supply 2026

Summary

The tender concerns the supply of 12,680 doses of antineoplastic medicines to Plzen University Hospital over four years from the signing of the purchase contract. The estimated total value is CZK 244,100,000. The procurement is divided into four lots: a pertuzumab and trastuzumab combination, polatuzumab vedotin, entrectinib and rituximab. The notice states these estimated annual quantities: 740 ampoules of the combination at 600 mg/600 mg and 60 ampoules at 1,200 mg/600 mg; 380 ampoules of polatuzumab vedotin at 30 mg and 60 ampoules at 140 mg; 1,800 dosage units of 200 mg entrectinib; and 90 ampoules of 1,400 mg rituximab and 40 ampoules of 1,600 mg rituximab. Offers will be evaluated separately for each lot, with price as the sole award criterion in each lot; the price assessed is the price including VAT for the lot's estimated total annual quantity. Bidders may submit offers for up to four lots and may be awarded all four. Offers must be submitted electronically by 6 November 2026 at 09:00. Precise exclusion grounds and qualification and compliance requirements must be checked in the tender documents.